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Metabolic syndrome (MS) is the concurrence of multiple metabolic abnormalities
associated with the development and progression of atherosclerosis.1 MS is incre-
asingly common, and represents a global public health problem.2,3 Meta-analyses
found that the MS increases the risk for cardiovascular disease and all-cause
mortality.4-6 Solymoss, et al.7 found that MS was present in as many as 51% of
patients with documented coronary artery disease (CAD).
However, it has been reported that MS is a marker of cardiovascular disease
risk, but not above and beyond the risk associated with its individual compo-
nents.8,9 Therefore, the number of markers of MS may be more useful than MS per
se to predict the severity of CAD, and it has been used instead of a binary
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Purpose: Metabolic syndrome (MS) has been reported as a potential risk factor of
coronary artery disease (CAD). The aims of this study were to assess whether there
was a relationship between MS score and CAD angiographic severity, and to
assess the predictive value of individual components of MS for CAD. Materials
and Methods: We retrospectively enrolled 632 patients who underwent coronary
angiography for suspected CAD (394 men, 61.0 ± 10.6 years of age). MS was
defined by the National Cholesterol Education Program criteria with the waist
criterion modified into a body mass index (BMI) of more than 25 kg/m2. The MS
score defined as the number of MS components. CAD was defined as > 50%
luminal diameter stenosis of at least one major epicardial coronary artery. CAD
angiographic severity was evaluated with a Gensini scoring system. Results: Of
the patients, 497 (78.6%) had CAD and 283 (44.8%) were diagnosed with MS. The
MS score was significantly related to the Gensini score. High fasting blood glucose
(FBG) was the only predictive factor for CAD. A cluster including high FBG,
high blood pressure (BP), and low high-density lipoprotein cholesterol (HDL-C)
showed the highest CAD risk. Conclusion: The MS score correlates with the
angiographic severity of CAD. The predictive ability of MS for CAD was carried
almost completely by high FBG, and individual traits with high BP and low HDL-
C may act synergistically as risk factors for CAD.
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INTRODUCTION
definition of MS in several studies.10,11 Each abnormality
promotes atherosclerosis independently, but when cluster-
ed together, these metabolic disorders are increasingly
atherogenic and enhance the risk of developing CAD and
cardiovascular events.12-14
The objectives of our study were to assess the relation-
ship between the MS score and the angiographic severity
of CAD, and to assess the predictive value of the indivi-
dual components of MS for CAD.
Subjects
From January 1, 2007 to December 31, 2007, we collected
clinical, biochemical, and angiographic information from
632 consecutive patients who underwent elective coronary
angiography at the Heart Center at Gangnam Severance
Hospital, Yonsei University College of Medicine. Patients
with recent myocardial infraction (MI), which could poten-
tially affect blood glucose and lipid levels, were excluded
from this study.
Definition of metabolic syndrome
The presence of MS was determined using the Third Adult
Treatment Panel (ATP III) of the National Cholesterol
Education Program (NCEP) criteria with the waist criter-
ion modified into a body mass index (BMI) of more than
25 kg/m2.12,13,15 The high blood pressure (BP) criterion was
defined as > 130/85 mmHg or being already on antihyper-
tensive medication. Impaired fasting glucose was defined
by a fasting blood glucose (FBG) of ≥ 110 mg/dL or being
already on oral hypoglycemic agents or insulin. Low high-
density lipoprotein cholesterol (HDL-C) was defined as
< 40 mg/dL in men and < 50 mg/dL in women. Hypertri-
glycemia was defined as fasting triglyceride (TG) ≥ 150
mg/dL. Those who had 3 or more of these 5 components
were classified as having MS. Patients were divided into 6
groups according to the number of constituents (0 to 5) of
MS- or MS score.
Biochemical tests
Venous sampling was collected in the early morning after
an overnight fasting prior to elective coronary angiography
using standard venipuncture technique. Insulin resistance
was evaluated by the homeostatic model assessment (HO-
MA) as described by Matthews, et al.16 This is defined by
the product of the fasting glucose and fasting insulin
divided by a constant. Thus, the HOMA index = [{fasting
insulin (U/mL)}×{fasting glucose (mmol/L)}] / 22.5. The
low-density lipoprotein cholesterol (LDL-C) concentration
was estimated by the formula by Friedewald, et al.17 For
subjects with serum TG levels ≥ 400 mg/dL, LDL-C was
directly measured by an enzymatic method (Cholestest®-
LDL, Sekisui medical Co., Ltd., Tokyo, Japan).
Angiographic assessment
Coronary angiography was performed by the Judkins tech-
nique through femoral artery access. The angiographic
characteristics, which included lesion location and percen-
tage stenosis, of all coronary lesions in the index coronary
angiogram were obtained by thoroughly reviewing the
angiogram. CAD was defined as > 50% luminal diameter
stenosis of at least one major epicardial coronary artery.
The Gensini scoring system was used to calculate coronary
disease severity.18 This method defines narrowing of the
lumen of the coronary arteries as 1 for 1-25% stenosis, 2
for 26-50% stenosis, 4 for 51-75% stenosis, 8 for 76-90%
stenosis, 16 for 91-99%, and 32 for total occlusion. The
score is then multiplied by a factor that represents the im-
portance of the lesion’s location in the coronary artery
system. For the location scores, 5 points were given for the
left main lesion; 2.5 for the proximal left anterior descend-
ing (LAD) or left circumflex (LCX) artery; 1.5 for the mid
segment LAD and LCX; 1 for the distal segment of LAD
and LCX, first diagonal branch, first obtuse marginal bran-
ch, right coronary artery, posterior descending artery, and
intermediate artery; and 0.5 for the second diagonal and
second obtuse marginal branches. The grades of luminal
narrowing were determined according to the consensus
opinion of two experienced interventional cardiologists.
Statistical analyses
Baseline demographic and laboratory data are presented as
mean ± SD for continuous variables and frequencies for
discrete variables. Comparisons among groups were cal-
culated with an analysis of variance for continuous variables
and Pearson’s chi-square test for discrete variables. Correla-
tions between the MS score and Gensini score were exa-
mined by linear regression analysis. The probability of
CAD occurrence in relation to MS, its single traits, and their
combinations were estimated as odds ratio (OR) [95%
confidence interval (CI)]. All data were analyzed using
statistical software SPSS for windows version 13.0 (SPSS
Inc., Chicago, IL, USA).
Baseline characteristics
A total of 632 patients (394 men, 61.0 ± 10.6 years of age)
were enrolled in this study. Of the 632 patients studied,
497 (78.6%) had CAD and 283 (44.8%) were diagnosed
with MS. The distribution of patients with 0 to 5 MS scores
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RESULTS
is listed in Table 1. In most groups, high BP was the most
frequent abnormality, followed by low HDL-C, high BMI,
high FBG, and high TG.
Demographic and biochemical characteristics of patients
with and without MS are presented in Table 2. There were
no significant differences in age, sex, height, or smoking
between the two groups. Patients with MS had higher total
cholesterol, TG, and LDL-C, and lower HDL-C. However,
the difference in LDL-C was marginally significant. MS
patients also had higher dysglycemia indexes. Particularly
striking were the differences in serum insulin and HOMA
indexes.
Coronary artery disease severity
Patients with and without MS did not differ in the preval-
ence of CAD and diseased vessel numbers (Table 3). How-
ever, patients with MS had severer CAD as assessed by the
Gensini score compared to patients without MS (23.3 ±
29.2 vs. 15.5 ± 23.4, p = 0.002). Interestingly, although
there were no significant differences in baseline charac-
teristics such as age, sex, height, or smoking among the
subgroups stratified by the MS score, an increasing MS
score was significantly related to the severity of CAD on
the coronary angiography. Fig. 1 demonstrates the relation-
ship between the MS score and CAD severity as assessed
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Table 1. Relative Frequency of Various Markers of Metabolic Syndrome and Clinical Characteristics Accord-
ing to the Metabolic Syndrome Score
MS score 0 (n = 38) 1 (n = 109) 2 (n = 202) 3 (n = 155) 4 (n = 99) 5 (n = 29)
High BMI* 0 (0%) 25 (23%) 82 (41%) 107 (69%) 80 (81%) 29 (100%)
High FBG� 0 (0%) 15 (14%) 62 (31%) 83 (54%) 77 (78%) 29 (100%)
High BP� 0 (0%) 38 (35%) 138 (68%) 125 (81%) 89 (90%) 29 (100%)
High TG§ 0 (0%) 4 (4%) 28 (16%) 49 (33%) 62 (63%) 29 (100%)
Low HDL-C‖ 0 (0%) 27 (25%) 94 (47%) 101 (65%) 88 (89%) 29 (100%)
Age (yrs) 61 ± 13 62 ± 10 61 ± 11 60 ± 10 62 ± 10 61 ± 11
Male 28 (74%) 69 (63%) 126 (62%) 93 (60%) 63 (64%) 15 (52%)
Smoking 17 (45%) 67 (62%) 114 (56%) 87 (56%) 46 (47%) 17 (59%)
MS, metabolic syndrome; BMI, body mass index; FBG, fasting blood glucose; BP, blood pressure; TG, triglyceride; HDL-C, high-density 
lipoprotein cholesterol.
* > 25 kg/m2.
�≥ 110 mg/dL.
� > 130/85 mmHg.
§ ≥ 150 mg/dL.
‖For men < 40 mg/dL; for women < 50 mg/dL.
Table 2. Clinical and Biochemical Characteristics of Patients with and without Metabolic Syndrome
Without MS (n = 349) With MS (n = 283) p value
Age (yrs) 61.0 ± 10.8 61.0 ± 10.4 0.984
Male 223 (64%) 171 (60%) 0.371
Height (cm) 162.9 ± 8.4 162.7 ± 8.9 0.799
Weight (kg) 64.0 ± 9.9 70.3 ± 10.2 < 0.001
BMI (kg/m2) 24.2 ± 2.8 26.5 ± 2.6 < 0.001
Smoking 151 (43%) 131 (47%) 0.401
Hypertension 176 (50%) 243 (86%) < 0.001
Diabetes 45 (13%) 139 (49%) < 0.001
Cholesterol (mg/dL) 152.9 ± 32.5 160.0 ± 35.9 0.006
TG (mg/dL) 101.4 ± 42.5 166.8 ± 49.9 < 0.001
HDL-C (mg/dL) 47.1 ± 14.5 39.0 ± 8.1 < 0.001
LDL-C (mg/dL) 92.8 ± 28.2 97.6 ± 32.8 0.046
Lipoprotein (a) (mg/dL) 24.3 ± 28.4 21.0 ± 29.3 0.146
FBG (mg/dL) 98.7 ± 19.7 115.8 ± 37.0 < 0.001
Serum insulin (µIU/mL) 7.8 ± 7.8 12.5 ± 15.2 < 0.001
HOMA index 2.0 ± 2.4 3.6 ± 4.7 < 0.001
MS, metabolic syndrome; BMI, body mass index; TG, triglyceride; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein 
cholesterol; FBG, fasting blood glucose; HOMA, homeostatic model assessment.
by the Gensini score system.
Predictive ability for CAD of MS and its components
The unadjusted and adjusted predictive abilities for angio-
graphic CAD of MS and its individual components are
shown in Fig. 2. Although a diagnosis of MS was associated
with the CAD severity assessed by the Gensini score, MS
per se did not predict the presence of CAD. Individually,
high FBG was the only predictive factor for CAD in uni-
variate analysis OR 2.070, 95% CI 1.371-3.124, p = 0.001).
Adjustment for other demographic features, LDL-C, and
individual MS constituents did not diminish this association
(OR 1.973, 95% CI 1.297-3.000, p = 0.002). Low HDL-C,
high BMI, high BP, and high TG were not predictive of
CAD in univariate and multivariate analyses.
The OR for CAD risk of different phenotypes in high
FBG are presented in Table 4. High BP as a companion
increased the OR significantly to 2.579. The other single
trait of significance was low HDL-C. Among the triads the
cluster with high BP and low HDL-C was the highest risk
(OR 3.731). Among the quartets, only combinations includ-
ing high BP and low HDL-C were associated with increas-
ed risk (OR 3.256 and 3.167). The OR for the quintet was
not significantly increased (OR 1.769, 95% CI 0.572-5.471,
p = 0.322). High FBG, high BP, and low HDL-C are signi-
ficant contributors to CAD risk.
In this study, patients with and without MS did not differ
in the prevalence of CAD and diseased vessel numbers,
but patients with MS had severer CAD as assessed by the
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DISCUSSION
Table 3. Angiographic Characteristics of Patients with and without Metabolic Syndrome
Without MS (n = 349) With MS (n = 283) p value
CAD 302 (87%) 247 (87%) 0.782
Normal or minimal 47 (14%) 36 (13%) 0.224
1 vessel disease 98 (28%) 72 (25%)
2 vessel disease 149 (43%) 112 (40%)
3 vessel disease 55 (16%) 63 (22%)
Gensini score 15.5 ± 23.4 23.3 ± 29.2 0.002
MS, metabolic syndrome; CAD, coronary artery disease.
Fig. 1. The relationship between the metabolic syndrome score and coronary
artery disease severity assessed by the Gensini score.
Fig. 2. Odds ratio plots for metabolic syndrome and its components as a predictor of the presence of angiographic coronary artery disease. MS,
metabolic syndrome; FBG, fasting blood glucose; BP, blood pressure; HDL-C, high-density lipoprotein cholesterol; TG, triglyceride; BP, blood
pressure; BMI, body mass index; UV, univariate analysis; MV, multivariate analysis.
Gensini score compared to patients without MS. 
One key conceptual advance made with the introduction
of MS as a clinically measurable entity was the recognition
of abdominal obesity as its most prevalent form.12,19 MS is
determined by the presence of 3 or more of quantitatively
identified markers. From the clinical perspective, it has
been questioned whether MS improves cardiovascular risk
prediction, beyond previously used tools for coronary heart
disease.20-24 Some studies have assessed whether metabolic
syndrome predicts the risk of cardiovascular diseases or a
surrogate such as subclinical atherosclerosis.25,26 In the
majority of these studies the outcome with which the meta-
bolic syndrome was to be related was atherosclerotic vas-
cular disease, either coronary heart disease alone or stroke.
However, in some studies, MS and its components are asso-
ciated with type 2 DM but have weak or no association
with vascular risk, suggesting that attempts to define a
criteria that simultaneously predict risk for both cardiova-
scular disease and DM are unhelpful.23,27,28
The fact that the 5 variables are used as “present” or
“absent” likely makes these screening tools less than per-
fect for the optimal diagnosis of the MS. Furthermore,
there is a mosaic of combinations of 3 of the 5 criteria which
makes it very unlikely that all these subgroups are similar
entities from a pathophysiological standpoint and clinical
prognosis.29 The central issue from an epidemiological
perspective is whether MS predicts cardiovascular disease
more than its individual components. It has been reported
that MS is a marker for cardiovascular disease risk, but not
above and beyond the risk associated with its individual
components.8,9 Therefore, the number of markers of MS
may be more useful than MS per se to predict the severity
of CAD.10 The results of our study showed that the increased
MS score was significantly related to the angiographic
severity of CAD. The statistical association with an increas-
ing number of MS features can be explained by the increas-
ing impact of multiple risk factors.
We also evaluated the ability of MS and its individual
components to predict angiographic CAD. Type 2 DM has
long been recognized as a significant risk factor for CAD
and has been acknowledged as a CAD equivalent.13 In the
present study, increased FBG was the only significant pre-
dictor of CAD although high BP, decreased HDL-C, and
increased BMI were the three most frequently observed
characteristics.
However, it has been demonstrated that the presence of
MS increased the risk of cardiovascular events ten-fold
even in patients with DM.30 Therefore, the increased risk
appears to be related to risk factor clustering associated
with MS.31,32 Individual components may interact synergi-
stically in accelerating the progression of atherosclerosis.
Analysis of the 11 possible combinations of individual MS
components reveals a striking heterogeneity in their ORs
as CAD risk factors. As shown in Table 4, the ORs of these
11 phenotypes vary in a wide range from 1.358 to 3.731,
depending upon individual components. MS clusters includ-
ing high FBG, high BP, and low HDL-C are clearly asso-
ciated with the highest CAD risk. Our investigation demon-
strates that CAD risk strongly depends on the individual
components.
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Table 4. Odds Ratios for Coronary Artery Disease of Different Phenotypes in High Fasting Blood Glucose
Phenotype Odds ratio (95% CI) p value
HFBG alone (n = 15) 2.070 (1.371 - 3.124) < 0.001
HFBG + HBP (n = 37) 2.579 (1.492 - 4.457) < 0.001
HFBG + LHDL (n = 16) 2.489 (1.441 - 4.299) 0.001
HFBG + HTG (n = 1) 1.864 (0.992 - 3.505) 0.053
HFBG + HBMI (n = 8) 1.716 (0.990 - 2.973) 0.054
HFBG + HBP+LHDL (n = 24) 3.731 (1.748 - 7.797) < 0.001
HFBG + HBP + HTG (n = 9) 2.677 (1.229 - 5.832) 0.013
HFBG + HBP + HBMI (n = 34) 2.963 (1.440 - 6.098) 0.003
HFBG + LHDL + HTG (n = 5) 2.286 (1.066 - 4.902) 0.034
HFBG + LHDL + HBMI (n = 9) 1.699 (0.837 - 3.449) 0.143
HFBG + HTG + HBMI (n = 1) 1.532 (0.702 - 3.346) 0.284
HFBG + HBP + LHDL + HTG (n = 20) 3.256 (1.190 - 8.908) 0.022
HFBG + HBP + LHDL + HBMI (n = 37) 3.167 (1.223 - 8.202) 0.018
HFBG + HBP + HTG + HBMI (n = 11) 2.412 (0.920 - 6.324) 0.073
HFBG + LHDL + HTG + HBMI (n = 10) 1.358 (0.555 - 3.323) 0.503
HFBG + HBP + LHDL + HTG + HBMI (n = 29) 1.769 (0.572 - 5.471) 0.322
HFBG, high fasting blood glucose; HBP, high blood pressure; LHDL, low high-density lipoprotein cholesterol; HTG, high triglyceride; 
HBMI, high body mass index.
The present study shares the limitations with other non-
randomized, retrospective studies, including the possible
presence of selection bias and uncorrected confounding. In
the subgroup analysis in the patients without DM, high
FBG did not show any significance in the prediction of
CAD. The subjects in our study were patients who were
admitted for clinically suspected CAD, and about 30% of
the subjects had DM. Therefore, selection bias and a high
prevalence of DM may affect the results. 
The presence of abdominal obesity is more highly cor-
related with metabolic risk factors than is BMI. Thus, the
simple measurement of waist circumference, with sex speci-
fic thresholds, was recommended by ATP III to identify
the body weight component of MS.12,13 However, because
waist circumference was not available, we used a BMI of
about 25 kg/m2, which was applied as a surrogate in a
previous report on the prevalence of obesity and MS in
Korean adults.33
In conclusion, the MS score correlates with the angio-
graphic severity of CAD. The predictive ability of MS for
CAD was carried almost entirely by high FBG, and indivi-
dual traits with high BP and low HDL-C seemed to act
synergistically as risk factors for CAD.
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